title: Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
abstract: Lenalidomide is approved for red blood cell (RBC) transfusion-dependent anemia due to low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDSs) associated with a chromosome 5q deletion with or without additional cytogenetic abnormalities. We report results of a multicenter, phase 2 trial evaluating lenalidomide therapy for transfusion-dependent patients with low- or int-1-risk MDS without deletion 5q. Eligible patients had 50,000/mm(3) or more platelets and required 2 U or more RBCs within the previous 8 weeks; 214 patients received 10 mg oral lenalidomide daily or 10 mg on days 1 to 21 of a 28-day cycle. The most common grade 3/4 adverse events were neutropenia (30%) and thrombocytopenia (25%). Using an intention-to-treat analysis, 56 (26%) patients achieved transfusion independence (TI) after a median of 4.8 weeks of treatment with a median duration of TI of 41.0 weeks. In patients who achieved TI, the median rise in hemoglobin was 32 g/L (3.2 g/dL; range, 10-98 g/L [1.0-9.8 g/dL]) from baseline. A 50% or greater reduction in transfusion requirement occurred in 37 additional patients, yielding a 43% overall rate of hematologic improvement (TI response + ||>or= 50% reduction in transfusion requirement). Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1-risk MDS who lack the deletion 5q karyotypic abnormality.
authors: Rush University Medical Center, Chicago, IL, USA.
authors: Azra
authors: A
authors: Raza
authors: James A
authors: JA
authors: Reeves
authors: Eric J
authors: EJ
authors: Feldman
authors: Gordon W
authors: GW
authors: Dewald
authors: John M
authors: JM
authors: Bennett
authors: H Joachim
authors: HJ
authors: Deeg
authors: Luke
authors: L
authors: Dreisbach
authors: Charles A
authors: CA
authors: Schiffer
authors: Richard M
authors: RM
authors: Stone
authors: Peter L
authors: PL
authors: Greenberg
authors: Peter T
authors: PT
authors: Curtin
authors: Virginia M
authors: VM
authors: Klimek
authors: Jamile M
authors: JM
authors: Shammo
authors: Deborah
authors: D
authors: Thomas
authors: Robert D
authors: RD
authors: Knight
authors: Michele
authors: M
authors: Schmidt
authors: Kenton
authors: K
authors: Wride
authors: Jerome B
authors: JB
authors: Zeldis
authors: Alan F
authors: AF
authors: List
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001803:Blood Transfusion; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D005260:Female; D006801:Humans; D007621:Karyotyping; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide